Program
Insulin
Also written as “Inhaled Insulin”, “Subcutaneous Insulin” and “Inhaled insulin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Drug-Related Side Effects and Adverse Reactions, led by 14 companies.
Drug pageInsulin: every studyMany companies study it; this page follows only the 33 they lead. All 272 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 110 open or running | phase 4since Jan 3, 2007 | Aug 22, 2005 | none ahead |
| Oramedits history only | 50 open or running | phase 3since Oct 22, 2020 | Jun 19, 2013 | none ahead |
| Eli Lillyits history only | 40 open or running | phase 3since Oct 19, 2006 | Jun 20, 2003 | none ahead |
| Oshadi Drug Administrationits history only | 20 open or running | phase 2since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| Sanofiits history only | 20 open or running | phase 4since Jul 23, 2014 | Sep 2, 2010 | none ahead |
| Baxter Healthcareits history only | 10 open or running | phase 1since Jul 31, 2006 | Jul 31, 2006 | none ahead |
| CPEX Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 23, 2009 | Feb 23, 2009 | none ahead |
| Generex Biotechnologyits history only | 10 open or running | phase 3since Apr 24, 2008 | Apr 24, 2008 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Dec 16, 2021 | Dec 16, 2021 | none ahead |
| Nastech Pharmaceuticalits history only | 10 open or running | phase 2since Feb 7, 2008 | Feb 7, 2008 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 14, 2009 | Sep 14, 2009 | none ahead |
| QDoseits history only | 10 open or running | phase 1since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Roger Newits history only | 10 open or running | phase 2since Jun 19, 2024 | Jun 19, 2024 | none ahead |
| Sam Chun Dang Pharm.its history only | 11 open or running | phase 1since May 26, 2026 | May 26, 2026 | none ahead |
Also a collaborator on its studies: Integrium, Alkermes, Kowa, Nextrials, eResearch Technology, Hoffmann-La Roche, ACM Pivotal Global Central Laboratory and Novo Nordisk.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Jun 20, 2003.
- Sep 14, 2009Profil Institut für Stoffwechselforschung’s first study: phase 1 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT00982254 · 10 enrolled · Germany
- Sep 2, 2010Sanofi’s first study: phase 3 study in Diabetes Mellitus, Type 1New to SanofiSanofi · NCT01194882 · 479 enrolled · Belgium, France, Netherlands and more
- Jan 17, 2013Oshadi Drug Administration’s first study: phase 2 study in Diabetes Mellitus, Type 1New to Oshadi Drug AdministrationOshadi Drug Administration · NCT01772251 · 10 enrolled · Israel
- Jun 19, 2013Oramed’s first study: phase 2 study in Diabetes Mellitus, Type 2New to OramedOramed · NCT01889667 · 30 enrolled · United States
- Oct 27, 2013Phase 2 study in Diabetes MellitusOshadi Drug Administration · NCT01973920 · 12 enrolled · Israel
- Jul 23, 2014Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT02201004 · 211 enrolled · Japan
- Oct 27, 2015Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02588950 · 11 enrolled · United States
- Dec 24, 2015Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT02653300 · 10 enrolled · Israel
- Oct 31, 2019Phase 2 study in Diabetes Mellitus, Type 1Oramed · NCT04150107 · 30 enrolled · United States
- Dec 9, 2019Named insulinINNProposed as its International Nonproprietary Name in WHO's List 122
- Oct 22, 2020Phase 3 study in Diabetes Mellitus, Type 2Oramed · NCT04606576 · 710 enrolled · United States
- Oct 28, 2020Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT04616014 · 7 enrolled · Belgium
- Dec 16, 2021Getz Pharma’s first study: phase 4 study in Drug-Related Side Effects and Adverse ReactionsNew to Getz PharmaGetz Pharma · NCT05161741 · 238 enrolled · Pakistan
- Jun 19, 2024Roger New’s first study: phase 2 study in Type 2 Diabetes Treated With InsulinNew to Roger NewRoger New · NCT06473662 · 153 enrolled · United Kingdom
- May 26, 2026Sam Chun Dang Pharm.’s first study: phase 1 study in Diabetes Mellitus, Type 1New to Sam Chun Dang Pharm.Sam Chun Dang Pharm. · NCT07634770 · 16 planned · Germany
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07634770Diabetes Mellitus, Type 1 · Germany | 1 | Recruiting | Sam Chun Dang Pharm. | Oct 2026 | 16 |
| NCT06473662Type 2 Diabetes Treated With Insulin · United Kingdom | 2 | Completed | Roger New | Jul 11, 2020 | 153 |
| NCT05161741Drug-Related Side Effects and Adverse Reactions · Pakistan | 4 | Completed | Getz Pharma | Nov 30, 2022 | 238 |
| NCT04616014Non-alcoholic Fatty Liver Disease · Belgium | 2 | Completed | Oramed | Jul 1, 2022 | 7 |
| NCT04606576Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Oramed | Jan 13, 2023 | 710 |
| NCT04150107Diabetes Mellitus, Type 1 · United States | 2 | Completed | Oramed | Feb 6, 2020 | 30 |
| NCT02653300Non-alcoholic Fatty Liver Disease · Israel | 2 | Completed | Oramed | Mar 1, 2020 | 10 |
| NCT02588950Diabetes Mellitus, Type 2 · United States | 1 | Terminated | Eli Lilly | May 25, 2017 | 11 |
| NCT02201004Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Sanofi | Jan 2016 | 211 |
| NCT01973920Diabetes Mellitus · Israel | 2 | Completed | Oshadi Drug Administration | Feb 2017 | 12 |
| NCT01889667Diabetes Mellitus, Type 2 · United States | 2 | Completed | Oramed | Nov 2013 | 30 |
| NCT01772251Diabetes Mellitus, Type 1 · Israel | 2 | Completed | Oshadi Drug Administration | Jun 2013 | 10 |
| NCT01194882Diabetes Mellitus, Type 1 · Belgium, France, Netherlands and more | 3 | Completed | Sanofi | Feb 1, 2018 | 479 |
| NCT00982254Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Profil Institut für Stoffwechselforschung | Nov 2001 | 10 |
| NCT00850161Diabetes Mellitus, Type 1 | 2 | Withdrawn | CPEX Pharmaceuticals | Aug 2009 | 0 |
| NCT00668850Diabetes Mellitus · United States, Bulgaria, Canada and more | 3 | UNKNOWN | Generex Biotechnology | Aug 2011 | 500 |
| NCT00624767Diabetes Mellitus · United States | 2 | Completed | Nastech Pharmaceutical | Apr 2008 | 18 |
| NCT00479258Diabetes Mellitus, Type 1 · United States | 3 | Terminated | Pfizer | Oct 2007 | 2 |
| NCT00426920Diabetes Mellitus · United States | 1 | UNKNOWN | QDose | 14 | |
| NCT00418522Diabetes Mellitus, Type 2 · United States, Puerto Rico | 4 | Completed | Pfizer | Aug 2008 | 413 |
| NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | May 2008 | 379 |
| NCT00358553Healthy · Germany | 1 | Completed | Baxter Healthcare | ||
| NCT00282971Diabetes Mellitus, Type 2 · Canada, France, Greece and more | 3 | Terminated | Pfizer | Feb 19, 2008 | 354 |
| NCT00150410Diabetes Mellitus · United States, Australia, Brazil and more | 3 | Completed | Pfizer | 626 | |
| NCT00143338Diabetes Mellitus, Type 2 · United States | 2 | Completed | Pfizer | 20 | |
| NCT00143104Diabetes Mellitus, Type 1 · United States | 2 | Completed | Pfizer | 20 | |
| NCT00139659Asthma · United States, Brazil, Canada and more | 3 | Completed | Pfizer | Oct 2008 | 288 |
| NCT00138671Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Terminated | Pfizer | Sep 2008 | 105 |
| NCT00137046Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Terminated | Pfizer | Dec 2008 | 582 |
| NCT00136916Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Terminated | Pfizer | Dec 2008 | 635 |
| NCT00134147Diabetes Mellitus · United States, Canada, France and more | 3 | Completed | Pfizer | 1,100 | |
| NCT00099515Diabetes Mellitus, Type 2 · United States, Argentina, Portugal and more | 2 | Completed | Eli Lilly | 97 | |
| NCT00063128Diabetes Mellitus, Type 1 · United States | 2 | Completed | Eli Lilly | 119 |
How it is read
Names in the registry
- “Insulin”, 13 entries
- “Inhaled Insulin”, 5 entries
- “Subcutaneous Insulin”, 3 entries
- “Inhaled insulin”, 3 entries
- “Inhaled Insulin (Exubera)”, 2 entries
Codes read as this program: LY041001.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 22 studies
- Diabetes Mellitus, Type 1, 12 studies
- Diabetes Mellitus, 8 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
- Drug-Related Side Effects and Adverse Reactions, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.